Sign Up
OverviewAPI
Arcutis partners with Sato Pharmaceutical in Japan to develop and market roflumilast, a non-steroidal treatment for skin diseases. The deal involves a $25 million upfront payment, potential milestone payments of up to $40 million, and royalties. Roflumilast targets conditions such as plaque psoriasis and atopic dermatitis, with Arcutis maintaining rights for the U.S. and other regions.

Ask a question